{
    "code": "02024727",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02024727",
    "time": "2019-06-28 03:04:00",
    "許可證字號": "衛署藥輸字第024727號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "111\/10\/23",
    "發證日期": "106\/10\/06",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202472708",
    "中文品名": "蕾莎瓦膜衣錠 200 毫克",
    "英文品名": "Nexavar film-coated tablets 200mg",
    "適應症": "轉移性或無法手術切除且不適合局部治療或局部治療失敗之晚期肝細胞癌(HCC)。\r\n晚期腎細胞癌(RCC)且已接受interferon-alpha或interleukin-2治療失敗，或不適合以上兩種藥物治療之病患。\r\n放射性碘治療無效之局部晚期或轉移性的進行性(progressive)分化型甲狀腺癌(DTC)。",
    "劑型": "116膜衣錠",
    "包裝": "8~1000錠鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": "SORAFENIB TOSYLATE, MICRONIZED",
    "主製造廠": {
        "申請商名稱": "1426201100  臺灣拜耳股份有限公司",
        "申請商地址": "台北市信義區信義路五段7號台北101大樓之53至54樓",
        "主製造廠": "",
        "製造廠名稱": "FDE0438200  Bayer AG"
    },
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013001610",
            "成分名稱": "SORAFENIB TOSYLATE, MICRONIZED",
            "含量描述": "(= sorafenib...200.0 mg )",
            "含量": "274.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "仿單核定本_1061225-106-12-25.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024727&Seq=054&Type=9"
        },
        {
            "title": "Carton___20100712.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024727&Seq=005&Type=8"
        }
    ]
}